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Abstract: Adjuvants can stimulate vaccine-induced immune responses and can contribute
decisively to antigen dose sparing when vaccine antigen production is limited, as for
example during a pandemic influenza outbreak. We earlier showed that GPI-0100, a
semi-synthetic saponin derivative with amphiphilic structure, significantly stimulates the
immunogenicity and protective efficacy of influenza subunit vaccine administered via a
systemic route. Here, we evaluated the adjuvant effect of GPI-0100 on a virosomal
influenza vaccine formulation. In contrast to influenza subunit vaccine adjuvanted with
GPI-0100, virosomal vaccine supplemented with the same dose of GPI-0100 provided
full protection of mice against infection at the extremely low antigen dose of 2 x 8 ng
hemagglutinin. Overall, adjuvanted virosomes elicited higher antibody and T cell
responses than did adjuvanted subunit vaccine. The enhanced immunogenicity of the
GPI-0100-adjuvanted virosomes, particularly at low antigen doses, is possibly due to a
physical association of the amphiphilic adjuvant with the virosomal membrane. These
results show that a combination of GPI-0100 and a virosomal influenza vaccine
formulation is highly immunogenic and allows the use of very low antigen doses
without compromising the protective potential of the vaccine.
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Abstract 
 
Adjuvants can stimulate vaccine-induced immune responses and can contribute decisively 
to antigen dose sparing when vaccine antigen production is limited, as for example during 
a pandemic influenza outbreak. We earlier showed that GPI-0100, a semi-synthetic 
saponin derivative with amphiphilic structure, significantly stimulates the 
immunogenicity and protective efficacy of influenza subunit vaccine administered via a 
systemic route. Here, we evaluated the adjuvant effect of GPI-0100 on a virosomal 
influenza vaccine formulation. In contrast to influenza subunit vaccine adjuvanted with 
GPI-0100, virosomal vaccine supplemented with the same dose of GPI-0100 provided full 
protection of mice against infection at the extremely low antigen dose of 2 x 8 ng 
hemagglutinin. Overall, adjuvanted virosomes elicited higher antibody and T cell 
responses than did adjuvanted subunit vaccine. The enhanced immunogenicity of the GPI-
0100-adjuvanted virosomes, particularly at low antigen doses, is possibly due to a 
physical association of the amphiphilic adjuvant with the virosomal membrane. These 
results show that a combination of GPI-0100 and a virosomal influenza vaccine 
formulation is highly immunogenic and allows the use of very low antigen doses without 
compromising the protective potential of the vaccine.  
 














For more than 60 years vaccination has been the primary strategy in the prevention of 
influenza virus infection [1-3]. Due to their low local reactogenicity, vaccines consisting 
of purified viral proteins, such as split or subunit vaccines, are currently preferred over 
whole inactivated virus (WIV) vaccines. Purified protein vaccines are as immunogenic as 
WIV vaccine in primed individuals. However, in unprimed subjects the immunogenicity 
of protein vaccines is relatively weak [3-5]. Vaccine immunogenicity can be enhanced by 
using adjuvant(s) which can boost immune responses against a specific antigen [6,7]. In 
addition, the use of adjuvants may allow antigen dose-sparing vaccination strategies 
which become very important in situations like pandemics in which vaccine demand may 
far exceed the available vaccine production capacity.  
 
Our earlier studies show that GPI-0100, a semi-synthetic derivative of saponin, is a 
promising candidate adjuvant for influenza subunit vaccine. In a mouse model, GPI-0100 
enhanced the antibody responses to intramuscularly injected subunit vaccine to a higher 
level than currently licensed adjuvants such as alum, MF59 or AS03 [8,9]. In addition, 
GPI-0100 effectively stimulated influenza-specific cellular immunity, which is crucial for 
immune memory formation and thus long-term protection. Remarkably, adjuvantation of 
subunit vaccine with GPI-0100 allowed a 25-fold reduction in hemagglutinin (HA) dose 
(down to 0.04 µg) without compromising the immunogenicity and protective capacity of 
the vaccine.  
 
Chemically, GPI-0100 is an amphiphilic molecule containing a triterpenoid backbone 
with sugar moieties and a fatty-acid side chain attached via the carboxyl group to one of 
the sugars [10,11]. The presence of this hydrophobic moiety gives the molecule an 
amphiphilic character and might enable physical association of GPI-0100 with 
membrane-containing antigen formulations thus further potentiating its immuno-
stimulating properties.  
 
Influenza virosomes are reconstituted viral membrane envelopes. Virosome production 
involves three steps: (1) solubilization of the virus membrane with a proper detergent, (2) 
removal of the virus core proteins and genetic material by ultracentrifugation and (3) 
reconstitution of the virus membrane by detergent extraction [12,13]. Influenza virosomes 
retain the structural and functional properties of the viral membrane envelope. Yet, the 
lack of viral genomes clears any concern for viral replication and infection. Functionally 
preserved virosomes can bind to cellular sialic acid receptors for hemagluttinin (HA), 
initiate receptor-mediated endocytosis and deliver encapsulated agents to the cytosol 
[12,14-16]. The virosomal HA is degraded in endosomes, resulting in MHC class II 
presentation and CD4+ T cell activation, which helps the development of CTL and B cell 
responses [12,16]. In addition, the repetitive arrangement of HA spikes on the virosome 
membrane can cross-link membrane-bound antibodies expressed on B cells and give 
strong activation signals to these cells [12,15,17]. Invivac® and InflexalV® are licensed 
virosomal influenza vaccines. Both vaccines have been shown to be well-tolerated and to 
induce immune responses as good as or even better than conventional inactivated 
influenza virus vaccines [18,19]. Importantly, unlike subunit vaccines, influenza 
virosomes provide a lipid membrane platform for physical association of amphiphilic 
adjuvants with the virosomal particle. This allows antigen-presenting cells to be activated 
by adjuvant and exposed to antigen at the same time. An earlier study in Balb/c mice 
showed that a single administration of influenza virosomes with a Toll-like receptor 2 
ligand incorporated in the membrane resulted in a 150-fold enhancement of IgG responses 
when compared to plain virosomes [15]. 
 
Here we evaluated the adjuvant effect of GPI-0100 on a virosomal influenza vaccine 
formulation as compared to a subunit vaccine formulation. To this end, mice were 
immunized intramuscularly (IM) with non-adjuvanted or GPI-0100-adjuvanted subunit or 
virosomal vaccine and immune responses were evaluated and the mice were challenged 
with a lethal dose of homologous virus.  Our data show that GPI-0100 enhanced the 
immunogenicity and protective capacity of influenza subunit and virosome vaccines to 
different extents. Overall, the adjuvanted virosomes elicited stronger humoral and cellular 
immunity than the adjuvanted subunit vaccine, especially at low antigen doses. Notably, 
only the adjuvanted virosomal, but not the subunit, vaccine remained fully protective at 
an antigen dose of 8 ng HA. We conclude that influenza virosomes admixed with GPI-
0100 provide a simple and yet potent influenza vaccine formulation especially with regard 
to antigen dose sparing. 
 
2. Materials and Methods 
 
2.1 GPI-0100 
GPI-0100 was purchased from Hawaii Biotech, Inc. (Aiea, HI, USA) as powder and was 
stored at 4 °C. The preparation and storage of GPI-0100 stock solution was described 
earlier [8]. 
 
2.2 Influenza virus and vaccines 
A stock of A/Puerto Rico/8/34 (H1N1) influenza virus (PR8), propagated on Madin–
Darby canine kidney (MDCK) cells, was kindly provided by Solvay Biologicals 
(currently Abbott Biologicals, Weesp, Netherlands). The virus was further propagated on 
embryonated chicken eggs, purified by sucrose gradient centrifugation, and the virus titer 
was determined by measuring the tissue-culture infectious dose 50 (TCID50) as previously 
described [8].  
 
Influenza virus was inactivated by β-propiolactone treatment followed by dialysis against 
HBS buffer (5 mM Hepes, 150 mM NaCl and 0.1 mM EDTA, pH 7.4) as described 
earlier [8]. The inactivated virus sample was processed to subunit vaccine using treatment 
with Tween 80 (0.6 mg/ml) and cetyltrimethylammonium bromide (CTAB, 3.0 mg/ml) 
followed by ultracentrifugation and detergent removal [8]. 
 
Virosomes were prepared from the inactivated influenza virus with 1,2-dihexanoyl-sn-
glycero-3-phosphocholine (DCPC), as described previously [20]. Briefly, inactivated PR8 
virus (1.5 μmol of viral phospholipid) was solubilized in 750 μl of 200 mM DCPC 
(Avanti Polar Lipids, Inc, Alabaster, AL, USA) in HBS buffer. The suspension was 
incubated on ice for 30 min and the nucleocapsid was removed from the preparation by 
ultracentrifugation. The DCPC was then removed by dialysis against HBS buffer 
overnight. The buffer was refreshed on the next day for another 4 hr of dialysis. 
Reconstituted virus membranes (virosomes) were separated from non-incorporated 
material on a discontinuous sucrose density gradient (10-50%, w/v) in HBS, in a SW55 
rotor at 33,000 rpm for 90 min. Subsequently, virosomes were dialyzed against HBS 
buffer to remove sucrose. Sterility of vaccine preparations was verified by plating on 
blood/agar plates and incubating for 24 hr at 37°C. 
 
The protein content of the subunit and the virosome vaccine was determined by a 
modified Lowry assay [21]. Hemagglutinin (HA) content was assumed to be equal to the 
total protein content since sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) proved that other proteins were present only in very minor amounts. 
Adjuvanted subunit or virosomal vaccines were prepared by mixing of the indicated 
amounts of antigen and GPI-0100 just before immunization. 
 
2.3 Animal handling 
The protocol for the animal experiments was approved by the Ethics Committee on 
Animal Research of the University of Groningen (Permit number: DEC 5896B and 
5896C).  Female Balb/c mice (Harlan, The Netherlands), aged 8–10 weeks, were grouped 
(n = 6 per group) and immunized IM with PR8 subunit or virosome vaccine alone or with 
GPI-0100 adjuvantation in a two-dose immunization regimen (day 0 and day 20). The 
amounts used are indicated in the Results section. Control mice were injected with HBS 
buffer. On day 27, mice were challenged by intranasal administration of 200 TCID50 PR8 
influenza virus in 50 μl of HBS buffer. Virus administration was carried out under 
isoflurane anesthesia to ensure deposition of the virus into the lungs. Mice were 
monitored twice a day at fixed time points for clinical signs of illness including weight 
loss, changes in behavior and appearance. Mice were bled and sacrificed on day 30. 
Serum samples were collected for ELISA assay. Spleens were harvested and splenocytes 
were used for ELISPOT assay. The lung lobes were collected in 1 ml PBS and the 
homogenized supernatants were stored at −80 °C freezer for lung virus titer detection. 
 
2.4 ELISA 
H1N1-specific antibody responses were determined by ELISA as described earlier [8]. 
Individual IgG titers were calculated as the 
10
log of the reciprocal of the sample dilution 
corresponding to an OD492 of 0.2. Individual IgG1 and IgG2a responses are given as 
concentration (μg/ml). 
 
2.5 Hemagglutination-inhibition (HAI) assay 
Serum samples were processed and subjected to HAI assay as earlier described [20]. 
2
log 
HAI titers for individual mice are presented. 
 
2.6 Elispot assays 
H1N1-specific IFN-γ and IL-4 responses were determined by Elispot assays as earlier 
described [8]. Numbers of influenza-specific IFNγ- or IL4-secreting cells per 500,000 
splenocytes from individual mice are given. 
 
2.7 Virus titration in lungs of challenged mice 
Virus titers were determined from lung homogenates as earlier described [8]. Results from 
individual mice are presented as 
10
log (virus titer per gram of lung tissue). 
 
2.8 Statistics 
The unpaired Student's t-test was used to determine if the differences in influenza-specific 
responses observed between groups of mice were significant. A p value of p < 0.05 was 
considered significant. 
 
3. Results  
 
3.1 Immunogenicity and protective capacity of influenza subunit or virosomal vaccine 
with or without GPI-0100  
Preliminary evaluation of influenza vaccine in different formulations was conducted at an 
antigen dose of 200 ng HA. Mice were immunized IM. twice on day 0 and 20 with 
subunit or virosomal vaccine alone or in the presence of 30 µg GPI-0100. One week after 
the second immunization, mice were challenged with homologous virus via the intranasal 
route. No significant weight loss was observed until sacrifice three days after challenge. 
Mock-immunized control mice developed an average lung virus titer of 10
6
 TCID50/g lung 
tissue (Figure 1A). The average titer was reduced by ≥ 4 logs in each of the immunized 
groups (p ≤ 0.0001 for all comparisons of mock-immunized and immunized groups). 
None of the mice immunized with plain subunit vaccine developed sterile immunity, 
while in 67% of the mice immunized with GPI-0100-adjuvanted subunit vaccine lung 
virus titers were below the detection limit. For virosomal vaccine, complete lung 
protection against virus growth was observed in 50% and 100% of the mice receiving 
plain virosomes and GPI-0100-adjuvanted virosomes respectively.  
 
We further analyzed HAI titers in serum samples collected from the mice described above. 
None of the mice that received plain influenza subunit vaccine developed a detectable 
serum HAI titer (Figure 1B). Only 1 out of the 6 mice receiving GPI-0100-adjuvanted 
subunit vaccine showed a detectable serum titer. On the other hand, influenza virosomes 
induced detectable HAI titers in 3 and 4 out of the 6 immunized mice for plain and GPI-
0100-adjuvanted vaccine, respectively. The average HAI titer induced by the adjuvanted 
virosomes was significantly higher than that induced by adjuvanted subunit vaccine (p= 
0.0304).  
 
3.2 Protective capacity of GPI-0100-adjuvanted influenza subunit or virosomal vaccine at 
a reduced antigen dose  
To gain better insight into possible differences between GPI-0100-adjuvanted subunit and 
virosomal vaccines, we repeated the challenge experiment using a lower dose of GPI-
0100 (15 µg) and titrating the antigen dose down from 200 to 8 ng. No significant weight 
loss was observed three days after virus challenge. On day 4 post challenge, the non-
immunized control mice all showed more than 10% of weight loss (Figure 2A). One out 
of the 6 mice immunized with adjuvanted low-dose (8 ng) subunit vaccine also 
demonstrated severe weight loss and two others lost ≥5% of weight. The rest of the 
immunized and challenged mice, however, showed no significant weight changes (except 
one animal in the group immunized with adjuvanted virosomes at 40 ng HA).  
 All mice were sacrificed four days after challenge and virus titers were determined in the 
collected lung homogenates. The control mice developed an average lung virus titer of 
10
7.2
 TCID50/g lung tissue (Figure 2B). All mice that received adjuvanted vaccines 
containing more than 40 ng HA were completely or nearly completely protected 
fromvirus growth in the lungs regardless of the vaccine formulation used. At the lowest 
tested antigen dose of 8 ng HA, a significant difference in lung protection was observed 
between mice immunized with adjuvanted subunit or adjuvanted virosomal vaccine (p= 
0.0078). Though the lung virus titer in subunit-immunized mice was significantly reduced 
as compared to that in the control group (p=0.0096), only 2 out of the 6 immunized mice 
developed sterile immunity with lung virus titers below the detection limit. The other 
mice of the group, however, showed only partial or no protection. In contrast, GPI-0100-
adjuvanted virosomes provided full protection in all vaccinated mice even at the lowest 
antigen dose.  
 
3.3 Humoral immunogenicity of GPI-0100-adjuvanted subunit or virosomal vaccine at a 
reduced antigen dose  
Humoral immune responses elicited by GPI-0100-adjuvanted subunit or virosomal 
vaccines at different antigen doses were evaluated by performing H1N1-specific IgG 
ELISAs and HAI assays on serum samples collected from the mice described above under 
3.2. Pre-challenge serum samples collected on day 27 showed that GPI-0100-adjuvanted 
subunit and virosomal vaccine elicited comparable H1N1-specific IgG responses at an 
antigen dose of 200 ng HA (Figure 3A). However, at an antigen dose of 40 ng there was a 
trend towards higher IgG responses in the virosome group as compared to those in the 
subunit group. This trend became statistically significant at the lowest antigen dose of 8 
ng (p = 0.0091).  
 
HAI responses were measured in post-challenge serum samples collected upon sacrifice 
of the animals. Titers were clearly antigen dose-dependent (Figure 3B). All mice that 
received 200 ng HA + GPI-0100 developed high HAI titers. At an antigen dose of 40 ng 
HA, measurable HAI titers were detected in 3 out of 6 or 5 out of 6 mice receiving the 
adjuvanted subunit or virosomal vaccine, respectively. For these two antigen doses, HAI 
titers elicited by the virosomal vaccine were significantly higher than those elicited by the 
subunit vaccine (p= 0.0128 and 0.0026, respectively). At 8 ng HA, HAI titers elicited by 
either of the vaccines were low. Only 1 of the subunit-immunized mice and 3 of the 
virosome-immunized mice developed detectable HAI titers. Thus, overall GPI-0100-
adjuvanted virosomes induced higher levels of influenza-specific antibodies than GPI-
0100-adjuvanted subunit vaccine. 
 
3.4 Phenotype of the antibody response elicited by GPI-0100-adjuvanted subunit and 
virosomal vaccine 
We further analyzed the phenotype of the antibody response by performing H1N1-
specific IgG1 and IgG2a ELISAs on the pre-challenge serum samples mentioned in 3.3. 
GPI-0100-adjuvanted subunit and virosomal vaccine elicited similar serum IgG1 
responses at all antigen doses tested (Figure 4A). On the other hand, the vaccine 
formulation did play a role in the induction of serum IgG2a (Figure 4B). While at higher 
antigen doses, the adjuvanted subunit vaccine was equally effective as the virosomal 
vaccine in induction of IgG2a, only the adjuvanted virosomes readily induced IgG2a at 
the low antigen dose of 8 ng HA, resulting in a significant difference between these two 
groups (p=0.0289). Nevertheless, for both formulations a Th2-oriented antibody response 
predominated since high levels of IgG1 were elicited at any given antigen dose. 
 
3.5 Cellular immunity of GPI-0100-adjuvanted subunit or virosomal vaccine at different 
antigen doses 
We next evaluated H1N1-specific cellular immunity elicited by the GPI-0100-adjuvanted 
vaccines by performing Elispot assays on post-challenge splenocytes collected upon 
sacrifice. H1N1-specific IFN-γ responses elicited by the adjuvanted subunit vaccines were 
generally very weak or undetectable (Figure 5A). The adjuvanted virosomes, on the other 
hand, effectively induced H1N1-specific IFN-γ responses at an antigen dose of 8 and 40 
ng HA, with an average of 69 and 136 IFN-γ-secreting cells per 5x105 splenocytes, 
respectively. Unexpectedly, H1N1-specific IFN-γ-secreting cells were barely induced in 
the adjuvanted 200 ng HA virosome group. In the animal groups that received 40 ng HA, 
a trend towards higher IFN-γ responses for the adjuvanted virosomes as compared to the 
subunit vaccine was observed. This trend reached statistical significance at 8 ng HA (p= 
0.0016). All of the vaccines tested readily induced H1N1-specific IL-4 responses after 
challenge. A strong antigen dose-dependent IL-4 response was observed for GPI-0100-
adjuvanted subunit vaccine (Figure 5B). At a high antigen dose of 200 ng HA, the 
adjuvanted subunit vaccine elicited significantly stronger IL-4 responses than did the 
adjuvanted virosomes (p=0.0023). At lower antigen doses, however, the adjuvanted 
virosomes elicited significantly stronger IL-4 responses than the adjuvanted subunit 
vaccine (p=0.0436 and 0.0094 for a comparison at 8 and 40 ng HA, respectively). Notably, 
Th1-skewed cellular immunity, predominated by IFN-γ-producing T cells, was observed 
only in mice that received GPI-0100-adjuvanted virosomes at an antigen dose of 40 ng 
HA or lower. Thus, the adjuvanted virosomes elicited a stronger and more Th1-oriented 




In an attempt to further improve the immunogenicity of influenza vaccines we compared 
in this study the effects of GPI-0100 adjuvantion on a subunit and a virosomal influenza 
vaccine formulation. Due to its amphiphilic nature GPI-0100 can potentially incorporate 
into virosomal membranes thus forming particles containing both antigen and adjuvant. In 
the absence of GPI-0100 subunit and virosomal vaccines induced similar levels of 
antibodies and reduction in lung virus titer after challenge. GPI-0100 stimulated the 
protective efficacy of both formulations but to different extents. At limiting amounts of 
antigen (8 ng HA) only the adjuvanted virosomal vaccine could completely prevent 
infection. Furthermore, the adjuvanted virosomes induced higher antibody titers and 
higher numbers of cytokine-producing T cells than adjuvanted subunit vaccine at antigen 
doses of 40 ng or lower,. These differences were not detected when an antigen dose of 
200 ng was used, presumably because at this relatively high dose of antigen, the nature of 
the vaccine formulation becomes less critical. Thus, overall GPI-0100-adjuvanted 
virosomes were superior to adjuvanted subunit vaccine, particularly at low antigen doses.  
 
Exploitation of the amphiphilic nature of saponin adjuvants to develop immunogenic 
vaccine delivery systems has been reported earlier. Immune-stimulating complexes 
(ISCOMs), composed of saponin, phospholipid, cholesterol and incorporated antigen are 
among the most potent saponin-containing formulations identified [24,25]. The ISCOM 
formulation contains cage-like particles approximately 40 nm in diameter. A challenge 
study in mice showed that subcutaneous delivery of a single dose of ISCOMs consisting 
of the saponin ISCOPREP
TM
703 and PR8 antigen protects mice from weight loss and 
death at an antigen dose of 0.5 µg HA [26]. Another study in mice using ISCOMs 
containing the saponin Quil A and the antigen from A/Taiwan/1/86 (H1N1) virus 
demonstrated that two subcutaneous immunizations with an antigen dose of 0.5 µg HA 
were required to provide complete lung protection against homologous challenge [27]. 
Here we show that mice receiving two intramuscular immunizations of GPI-0100-
adjuvanted PR8 virosomes were protected from weight loss and lung infection upon 
challenge even at the very low antigen dose of 8 ng HA. Hence, GPI-0100-adjuvanted 
virosomes provide a formulation which is relatively simple, exploits a marketed influenza 
vaccine formulation, is easy to produce, and at the same time performs as good as or even 
better than influenza ISCOMs.  
 
Influenza virosomes are 100-200 nm particles composed of the membrane lipids and spike 
proteins of influenza virus. Unlike influenza virus-like particles (VLPs), which are 
produced by infecting cells lines with genetically modified viral vectors containing 
influenza virus genes, influenza virosomes are produced from cultured influenza viruses 
with or without addition of extra lipids [13,17,28,29]. The safety and efficacy of 
virosomal influenza vaccines has been demonstrated to be as good as or even better than 
that of split or subunit vaccines in children, adults and healthy elderly or those with a 
medical condition [19,30-34]. Importantly, due to their membranous nature, virosomal 
vaccines provide a platform for the incorporation of lipophilic or amphiphilic adjuvants 
[35-40]. Such an integration of stimulatory signals from both antigen and adjuvant is 
expected to elicit robust immune responses [41,42].  
 
Adjuvanted virosomal vaccines can be produced by different methods. One way is to 
combine lipophilic/amphiphilic adjuvant and virosomal antigen during the process of 
virosome reconstitution. The adjuvant is mixed with solubilized viral membranes in the 
presence of solubilization agent. After incubation, the mixture is dialyzed against buffer 
for the removal of solubilization agent and formation of virosomes. Using this method, 
respiratory syncytial virus (RSV) virosomes with incorporated P3CSK4 or MPLA (TLR-2 
and TLR-4 ligand respectively) were prepared. The adjuvant-modified RSV virosomes 
were shown to induce significantly stronger Th1 immunity than non-adjuvanted 
virosomes and formalin-inactivated RSV and to induce full protection against RSV 
infection [35,36]. Addition of an amphiphilic adjuvant prior to virosome reconstitution 
has also been used successfully for the generation of influenza vaccines. A study on 
virosomal H5N1 vaccine shows that incorporation of the LPS-derivative LpxL1 
stimulates vaccine immunogenicity and skews immune responses towards a Th1 
phenotype [37]. Alternatively, adjuvants can be simply added to preformed virosomal 
vaccines. Cox et al. showed that addition of ISCOMATRIX (Matrix-M
TM
) to preformed 
H5N1 virosomes prior to injection significantly enhances the immunogenicity of the 
vaccine in both mice and humans [38-40]. Murine studies further show that Matrix-M-
adjuvanted virosomes elicit much stronger Th1 responses (IgG2a, IL-2, IFN-γ and IL-12) 
and higher frequencies of multifunctional Th1 CD4+ cells when compared to plain 
virosomes. In addition, for intranasal delivery only the Matrix-M-adjuvanted but not plain 
virosomes provide protection against homologous virus infection. The effectiveness of a 
simple admixture of adjuvant and virosomal antigen is further clarified in our study. 
Addition of GPI-0100 to preformed virosomal H1N1 vaccine prior to immunization was 
sufficient to strongly potentiate immune responses.  
 
While GPI-0100 does enhance immune responses when combined with influenza subunit 
vaccine which largely lacks lipids, our results indicate that it is considerably more potent 
when admixed with virosomes which consist of reconstituted viral membranes. We 
hypothesize that the potent immunogenicity and antigen dose-sparing capacity of GPI-
0100-adjuvanted virosomes are due to a physical association of the amphiphilic adjuvant 
molecule with the virosomal membrane. Yet, we so far do not have formal proof for this 
hypothesis. Preliminary results from particle size determination by use of Nanosight 
equipment show that GPI-0100 changes the average particle size of influenza virosomal 
but not subunit vaccines. Whether the observed phenomenon is caused by GPI-0100 
partitioning into the virosomal membrane vesicles or by reformation of GPI-0100-
disrupted virosomes, or by a combination of both, needs to be elucidated.  
 
In summary, we show that GPI-0100 is a very potent adjuvant when used in combination 
with virosomal influenza vaccine. Particularly at limiting amounts of antigen, GPI-0100 
adjuvanted virosomes elicited higher antibody titers and higher numbers of IFNγ-
producing T cells than equal amounts of adjuvanted subunit vaccine. Remarkably, 
complete lung protection against homologous challenge was achieved by two 
immunizations with only 8 ng HA formulated in adjuvanted virosomes. This indicates that 
adjuvantation of virosomal influenza vaccine with GPI-0100 is a very promising strategy 
for  antigen dose sparing as required in case of influenza pandemics. Yet, further 
characterization of the vaccine formulation and optimization of the ratio between GPI-
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7. Figure legends 
 
Figure 1. Lung protection and hemaglutination inhibition (HAI) titer elicited by 
influenza subunit or virosomal vaccine with and without GPI-0100. 
Mice (n=6 per group) were immunized intramuscularly on day 0 and day 20 with 0.2 μg 
A/PR/8 subunit or virosomal vaccine alone or adjuvanted with 30 μg GPI-0100. The 
control mice received HBS buffer. Mice were infected with live PR8 virus one week after 
the second immunization and were sacrificed 3 days after challenge for ex vivo analysis. 
(A) Lung virus titers. Virus titers are expressed as the 
10
log virus titer per gram of lung 
tissue for individual mice. The black line represents the geometric mean virus titer per 
group. Due to technical reasons, only 4 or 5 samples from mice receiving plain or GPI-
0100-adjuvanted virosomes, respectively, were available for lung virus titration. (B) Post-
challenge HAI titers. The results are expressed as the 
2
log HAI titers for individual mice. 
The black line represents the geometric mean HAI titer per group. The dotted line 
represents the detection limit. The stars indicate statistical differences between compared 
groups. Levels of significance are depicted as follows: *: p < 0.05, **: p < 0.01 and ***: p 
< 0.005.  
 
Figure 2. Protective capacity of GPI-0100-adjuvanted influenza subunit or virosomal 
vaccine at different antigen doses. 
Mice were immunized intramuscularly on day 0 and day 20 with PR8 subunit or 
virosomal vaccine at different antigen doses (8, 40, 200 ng HA), adjuvanted with 15 μg 
GPI-0100. Control mice received HBS buffer. Mice were infected with live PR8 virus one 
week after the second immunization and were sacrificed 3 days after challenge for ex vivo 
analysis. (A) Weight changes. The weight upon sacrifice (day 30) was compared to the 
weight prior to challenge (day 27) for each individual mouse. The black line represents 
the arithmetic mean of the relative weight change per group. (B) Lung virus titer.  
Determined as described in the legend to Figure 1. 
 
Figure 3. Humoral immune responses to GPI-0100-adjuvanted influenza subunit or  
virosomal vaccine at different antigen doses. 
Pre- and post-challenge serum samples from the mice described in the legend to Fig. 2 
were collected on day 27 and 37, respectively. A) Total IgG responses after two 
immunizations. 
10
log IgG titers of individual mice are given. The black line represents the 
geometric mean IgG titer per group. (B) Post-challenge HAI titers. Due to technical 
reasons, only 4 samples from the mice that received 8 ng HA subunit adjuvanted with 15 
μg GPI-0100 were available for the HAI assay.   
 
Figure 4. Phenotype of the influenza-specific antibody responses to GPI-0100-
adjuvanted influenza subunit or virosomal vaccine. 
Serum samples from the mice described in the legend to Fig. 3(A) were analyzed. (A) 
Influenza-specific IgG1 (μg/ml) of individual mice with arithmetic mean per group. (B) 
Influenza-specific IgG2a (μg/ml) of individual mice with arithmetic mean per group. 
 
Figure 5. Cellular immune responses to GPI-0100-adjuvanted influenza subunit or 
virosomal vaccine at different antigen doses. 
Spleen samples from the mice described in the legend to Fig. 2 were collected on day 37. 
Splenocytes were isolated and stimulated overnight with PR8 subunit antigen. (A) IFN-γ-
producing splenocytes per 5x10
5
 cells of individual mice with arithmetic mean per group. 
(B) IL-4-producing splenocytes per 5x10
5
 cells of individual mice with arithmetic mean 
per group.  
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